The issued patent claims cover systems for determining the activation state of more than one protein in a cell, where the system can utilize any detector, including cytometers and mass spectrometers. The ‘527 patent extends through September 2023 and is exclusively licensed by Nodality from Stanford University.
"The ‘527 patent is another important protection for our multifaceted approach to improving drug development through diverse applications of our Single Cell Network Profiling platform," said Laura Brege, CEO and President of Nodality, Inc.
"Nodality has carefully constructed a patent estate consisting of more than 30 issued and allowed patents in the US and abroad, with over 260 issued claims, particularly in relation to the detection of activatable proteins that can be analyzed in healthy and diseased tissues, as well as in response to the application of new therapeutic modalities. We believe we have a commanding IP position in our space, which is an important aspect of the value proposition we offer to current and potential collaborators."
In addition to the issued and allowed patents, Nodality’s intellectual property estate also consists of more than 60 patent applications both in the US and ex-US.